§ 01 Overview
Overview
Macrolide mTORC1 inhibitor, FDA-approved for transplant rejection and LAM; weekly off-label dosing extends lifespan in mice and showed benefits in the PEARL human trial.
FDA-approved for transplant rejection (1999) and LAM (2015). PEARL RCT (2025) is the first human longevity-endpoint trial.
§ 02 Mechanism
Mechanism of action
Rapamycin forms a complex with FKBP12 that inhibits mTORC1, dampening cell growth and protein synthesis pathways and activating autophagy. Intermittent dosing preserves mTORC1 recovery and appears to avoid mTORC2-related metabolic side effects.
- 01Extends mouse lifespan (Harrison 2009 and later)
- 02Improves physical and cognitive markers (PEARL trial)
- 03Potential senomorphic + autophagy-inducing effects
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 6 mg weekly (off-label longevity protocols)
- Route
- Oral
- Timing
- Same day weekly
- Frequency
- Weekly
- Cycle
- Continuous; reassess IGF-1, lipids, glucose
§ 04 Evidence
Evidence & research
FDA-approved for transplant rejection (1999) and LAM (2015). PEARL RCT (2025) is the first human longevity-endpoint trial.
FDA Status
FDA-approved (Rapamune NDA 021083) for transplant rejection and LAM.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
This promising anti-aging drugs just failed its human test - MEXC
This promising anti-aging drugs just failed its human test MEXC
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients - BioSpace
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients BioSpace
Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats - Vet Candy
Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats Vet Candy
Blockbuster drug raises questions of scientific colonialism - The Hindu
Blockbuster drug raises questions of scientific colonialism The Hindu
Rapamycin’s Effects on Human Aging Explored in New Study - Newsweek
Rapamycin’s Effects on Human Aging Explored in New Study Newsweek
FDA Gives Conditional Green Light to First-Ever Drug for Subclinical HCM in Cats: Felycin®-CA1 Now Available to Veterinarians - Vet Candy
FDA Gives Conditional Green Light to First-Ever Drug for Subclinical HCM in Cats: Felycin®-CA1 Now Available to Veterinarians Vet Candy
Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats - Business Wire
Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats Business Wire
First drug OK'd for most common heart condition in cats - News - VIN
First drug OK'd for most common heart condition in cats News - VIN
§ 07 Sourcing
Sourcing & supply
Regulatory status
FDA-approved
This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status.
Telehealth (Rx) · 2
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Mouth ulcers
- 02Immunosuppression at higher / daily dosing
- 03Dyslipidemia and glucose elevations
Contraindications
- 01Active infection
- 02Pregnancy
§ 10 References
Selected references
- 01
Harrison Nature — mouse lifespan
PMID: 19587680
- 02
PEARL trial
PMID: 40188830 (NCT04488601)